Please use this identifier to cite or link to this item:
|Title:||Antipsychotic treatment in older schizophrenia patients with extrapyramidal side effects in Asia (2001-2009)||Authors:||Xiang, Y.-T.
|Keywords:||Extrapyramidal side effects
|Issue Date:||Jul-2012||Citation:||Xiang, Y.-T., Kreyenbuhl, J., Dickerson, F.B., Ungvari, G.S., Wang, C.-Y., Si, T.-M., Lee, E.H.M., Chiu, H.F.K., Lai, K.Y.C., He, Y.-L., Yang, S.-Y., Chong, M.-Y., Tan, C.-H., Kua, E.-H., Fujii, S., Sim, K., Yong, M.K.H., Trivedi, J.K., Chung, E.-K., Udomratn, P., Chee, K.-Y., Sartorius, N., Shinfuku, N. (2012-07). Antipsychotic treatment in older schizophrenia patients with extrapyramidal side effects in Asia (2001-2009). International Journal of Clinical Pharmacology and Therapeutics 50 (7) : 500-504. ScholarBank@NUS Repository. https://doi.org/10.5414/CP201683||Abstract:||Objective: This study surveyed the prescribing patterns of antipsychotic medications in Asian older schizophrenia patients with extrapyramidal side effects (EPS) during the period between 2001 and 2009. Method: Information on 848 hospitalized patients with schizophrenia aged 60 or older was extracted from the database of the Research on Asian Psychotropic Prescription Patterns (REAP) study (2001 - 2009). Data from those patients with reported EPS from 8 Asian countries and territories including China, Hong Kong, Japan, Korea, Singapore, Taiwan, India and Malaysia were analyzed. The cross-sectional data of socio-demographic and clinical characteristics and antipsychotic prescriptions were collected using a standardized protocol and data collection procedure. Results: Of the 309/848 (36%) patients suffering from EPS, 210 patients (210/309; 68.0%) received at least one type of first generation antipsychotic (FGA), and 99 (99/309; 32.0%) received second generation antipsychotics (SGAs) only. Of SGAs prescribed in patients with EPS, risperidone was the most commonly used (100/309; 32.4%) followed by olanzapine (33/309; 10.7%) and quetiapine (25/309; 8.1%). Conclusions: FGAs were frequently used in Asian older schizophrenia patients with EPS. Considering the potential adverse effects of FGAs on existing EPS, the reasons for the frequent use of FGAs need to be urgently identified. ©2012 Dustri-Verlag Dr. K. Feistle.||Source Title:||International Journal of Clinical Pharmacology and Therapeutics||URI:||http://scholarbank.nus.edu.sg/handle/10635/125660||ISSN:||09461965||DOI:||10.5414/CP201683|
|Appears in Collections:||Staff Publications|
Show full item record
Files in This Item:
There are no files associated with this item.
checked on May 24, 2019
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.